Nykode Therapeutics Announces Updates on its Inverse Vaccine …
OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies ...
Home - Nykode
6 days ago · The Nykode Therapeutics platform is built around the Vaccibody molecule. Inducing fast, strong and long-lasting immune responses, and demonstrating a positive safety profile, our pioneering Vaccibody™ vaccine has the potential to treat many disease areas, including cancer.
Press Releases - Nykode
Nykode Therapeutics reports Q2 2024 Financial Results. 21/08/2024. Nykode Therapeutics Announces Strategic Repositioning of VB10.16 to Focus on Locally Advanced Cervical Cancer and Recurrent Metastatic Head and Neck Cancer. Load more.
Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine …
OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Nykode Therapeutics Announces Topline Conclusions Affirming …
OSLO, Norway, March 21, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Nykode Therapeutics Announces Updates on its Inverse Vaccine …
Nov 6, 2024 · About Nykode Therapeutics Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to antigen presenting cells (APC), employed with ...
Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine
OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Nykode Therapeutics Announces Advances in the Inverse Vaccine …
Mar 19, 2024 · Nykode employs its unique technology platform to pioneer the field of inverse vaccines, with the potential to develop high-precision treatments for autoimmune diseases.
Nykode Therapeutics Announces Positive Results from the
Sep 27, 2022 · Nykode’s vaccine candidate boosted Spike-specific T cell responses and induced de novo T cell responses to non-Spike antigens found across SARS-CoV-2 variants
Nykode Therapeutics (Formerly Vaccibody - Business Wire
Nov 23, 2021 · Nykode Therapeutics’ modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune...
- Some results have been removed